Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy
Ashot AvagimyanDepartment of Anatomical Pathology and Clinical Morphology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. Electronic address: [email protected]Mohammad SheibaniDepartment of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Razi Drug Research Centre, School of Medicine, Iran University of Medical Sciences, Tehran, IranNana PogosovaNational Medical Research Centre of Cardiology named after E. Chazov, Moscow, RussiaLusine MkrtchyanDepartment of Cardiology, Yerevan State Medical University after M. Heratsi, Yerevan, ArmeniaHasmik YeranosyanDepartment of Forensic Medicine, Yerevan State Medical University after M. Heratsi, Yerevan, ArmeniaAnahit AznauryanDepartment of Histology, Yerevan State Medical University after M. Heratsi, Yerevan, ArmeniaKarmen SahaakyanHead of Histology Department, Yerevan State Medical University after M. Heratsi, Yerevan, ArmeniaFederica FogacciResearch Fellow, Atherosclerosis and Metabolic Disorders Research Unit, Alma Mater Studiorum University of Bologna, Bologna, ItalyArrigo F.G. CiceroHypertension and Cardiovascular Risk Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy; Cardiovascular Medicine Unit, Heart, Chest and Vascular Dept., IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyDavood ShafieHead of Heart Failure Centre, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Science, Isfahan, IranNizal SarrafzadeganIsfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2023en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 3Использованных источников: 0